EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Hypofractionated radiosurgery for pituitary adenomas: a systematic review and meta-analysis

Fernando Cotrim Gomes, Diego Dias Freire Carvalho, Guilherme Gago, Anna Laura Lima Larcipretti, Gokberk Erol, Aysu İyigün Kabakci, Michael Weisman, Kevin Shiue, João Paulo Almeida

Neurosurgical Review · 16.11.2026 · 49 (1)

DOI: 10.1007/s10143-026-04592-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Neurosurgical Review, online erschienen am 16.11.2026. Verfasst von Fernando Cotrim Gomes und 8 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypofractionated stereotactic radiosurgery (HFSRS) has emerged as a treatment option for pituitary adenomas requiring radiotherapeutic management, particularly when proximity to the optic apparatus limits the use of single-fraction stereotactic radiosurgery (SRS). This systematic review and meta-analysis evaluated tumor control, endocrine outcomes, visual outcomes, and treatment-related complications after HFSRS for functioning and nonfunctioning pituitary adenomas. PubMed, Embase, and Web of Science were searched from inception through November 2025. Eligible studies reported outcomes after HFSRS for functioning or nonfunctioning pituitary adenomas using GammaKnife, CyberKnife, LINAC, Novalis, or other stereotactic platforms. The primary outcome was radiographic tumor control at last follow-up. Secondary outcomes included endocrine remission, visual worsening, new hypopituitarism, transient complications, and mortality. Random-effects generalized linear mixed models were used to pool proportions. Eighteen studies comprising 785 patients were included. Of these, 296 patients had functioning adenomas and 489 had nonfunctioning adenomas. CyberKnife was used in 12 studies, LINAC in three, and GammaKnife in three. Prescribed doses ranged from 15 to 35 Gy delivered in 2 to 5 fractions. Overall tumor control was achieved in 98% of cases (95% CI 96–99; I^2 = 0%), with similar rates among functioning and nonfunctioning adenomas. Among 629 patients with visual outcome assessment, visual worsening occurred in 2% (95% CI, 1% − 3%; I² = 0%). Endocrine remission among functioning adenomas was 46% (95% CI, 33% − 53%). New persistent hypopituitarism occurred in 6% of patients (95% CI, 4% − 11%), while transient complications occurred in 4% (95% CI, 2% − 7%). No cases of blindness or procedure-related mortality were reported. HFSRS provides high rates of tumor control with low rates of visual morbidity and new hypopituitarism in selected patients with pituitary adenomas. Prospective studies with standardized outcome definitions comparing this technique with traditional single-fraction therapy are needed.

Zitieren

APA

Gomes, F. C., Carvalho, D. D. F., Gago, G., Larcipretti, A. L. L., Erol, G., Kabakci, A. İ., Weisman, M., Shiue, K., & Almeida, J. P. (2026). Hypofractionated radiosurgery for pituitary adenomas: a systematic review and meta-analysis. Neurosurgical Review, 49(1). https://doi.org/10.1007/s10143-026-04592-4

Vancouver

Gomes FC, Carvalho DDF, Gago G, Larcipretti ALL, Erol G, Kabakci Aİ, et al. Hypofractionated radiosurgery for pituitary adenomas: a systematic review and meta-analysis. Neurosurgical Review. 2026;49(1). doi:10.1007/s10143-026-04592-4

BibTeX
@article{Gomes2026,
  author = {Gomes, Fernando Cotrim and Carvalho, Diego Dias Freire and Gago, Guilherme and Larcipretti, Anna Laura Lima and Erol, Gokberk and Kabakci, Aysu İyigün and Weisman, Michael and Shiue, Kevin and Almeida, João Paulo},
  title = {Hypofractionated radiosurgery for pituitary adenomas: a systematic review and meta-analysis},
  journal = {Neurosurgical Review},
  year = {2026},
  volume = {49},
  number = {1},
  doi = {10.1007/s10143-026-04592-4}
}
Kostenlos starten →